Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216794 · ClinicalTrials.gov registry record · Phase 2
Small Trial of Alendronate Impact on the Reservoir of HIV
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Not yet
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT07216794 is a Phase 2 study that has not yet begun recruiting, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 30 participants.
The verdict
NCT07216794, a Phase 2 study, has not yet begun recruiting, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This clinical trial is designed to test the effects of alendronate (ALN) on people living with HIV who are already receiving antiretroviral therapy (ART). Participants are randomly assigned in a 2:1 ratio to either receive alendronate or a placebo, and neither the participants nor the researchers know who is receiving the actual treatment. The goal is to see if alendronate can reduce the size and activity of the HIV-1 reservoir in these individuals.
Interventions
- OTHER Placebo
- DRUG Alendronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-06-27 |
| Est. Completion | 2027-05-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07216794
The ClinicalTrials.gov registry entry for NCT07216794 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07216794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07216794 about?
NCT07216794 is a clinical study titled "Small Trial of Alendronate Impact on the Reservoir of HIV". This clinical trial is designed to test the effects of alendronate (ALN) on people living with HIV who are already receiving antiretroviral therapy (ART). Participants are randomly assigned in a 2:1 ratio to either receive alendronate or a placebo, and neither the participants nor the researchers kn...
What is the current status of trial NCT07216794?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-06-27. Estimated completion is 2027-05-21.
What interventions are being tested in trial NCT07216794?
The interventions under investigation include: Placebo (OTHER), Alendronate (DRUG).
Who is sponsoring clinical trial NCT07216794?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.